A human antibody against human endothelin receptor type A that exhibits antitumor potency
Man‐Seok Ju, Hye-Mi Ahn, Seong‐Gu Han, Sanghwan Ko, Jung‐Hyun Na, Migyeong Jo, Chung Su Lim, Byoung Joon Ko, Yeon Gyu Yu, Won‐Kyu Lee, Youn‐Jae Kim, Sang Taek Jung
Abstract
Abstract Endothelin receptor A (ET A ), a class A G-protein-coupled receptor (GPCR), is involved in the progression and metastasis of colorectal, breast, lung, ovarian, and prostate cancer. We overexpressed and purified human endothelin receptor type A in Escherichia coli and reconstituted it with lipid and membrane scaffold proteins to prepare an ET A nanodisc as a functional antigen with a structure similar to that of native GPCR. By screening a human naive immune single-chain variable fragment phage library constructed in-house, we successfully isolated a human anti-ET A antibody (AG8) exhibiting high specificity for ET A in the β-arrestin Tango assay and effective inhibitory activity against the ET-1-induced signaling cascade via ET A using either a CHO-K1 cell line stably expressing human ET A or HT-29 colorectal cancer cells, in which AG8 exhibited IC 50 values of 56 and 51 nM, respectively. In addition, AG8 treatment repressed the transcription of inhibin βA and reduced the ET A -induced phosphorylation of protein kinase B and extracellular regulated kinase. Furthermore, tumor growth was effectively inhibited by AG8 in a colorectal cancer mouse xenograft model. The human anti-ET A antibody isolated in this study could be used as a potential therapeutic for cancers, including colorectal cancer.